[Initial experiences with the calcium antagonist tiapamil in the treatment of arterial hypertension].
24 hypertensive patients were treated with 300-450 mg tiapamil daily for 2-6 months. The antihypertensive effect of this new calcium entry blocking agent was expressed by a reduction even of extremely elevated blood pressures to the normotensive, but not to the hypotensive range, in 20 patients. The drug was well tolerated.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011437:Propylamines / Q000627:therapeutic use*; D013976:Tiapamil Hydrochloride
D011437:Propylamines; D013976:Tiapamil Hydrochloride
Erste Erfahrungen mit dem Calcium-Antagonisten Tiapamil in der Behandlung der arteriellen Hypertonie.